| Glenmark Pharmaceuticals (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Apremilast Tablets, 10 mg, 20 mg and 30 mg, the generic version of Otezla®1 Tablets, 10 mg, 20 mg and 30 mg, of Amgen Inc.
According to IQVIATM sales data for the 12-month period ending August 2023, the Otezla® Tablets, 10 mg, 20 mg, and 30 mg market achieved annual sales of approximately $3.7 billion. |